Chronic Lymphocytic Leukemia Clinical Trial

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Summary

This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.

View Eligibility Criteria

Eligibility Criteria

Stratum 1 Recipient Inclusion Criteria:

Age > 18 years and < 66 years (chemotherapy-based conditioning) or < 61 years (total body irradiation [TBI]-based conditioning) at the time of signing informed consent
Planned MAC regimen as defined per protocol
Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age < 35 years
Product planned for infusion is PBSC
HCT Comorbidity Index (HCT-CI) < 5

One of the following diagnoses:

Acute myeloid leukemia (AML) acute lymphoblastic leukemia (ALL), or other acute leukemia in 1st remission or beyond with ≤ 5% marrow blasts and no circulating blasts or evidence of extra-medullary disease. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
Patients with myelodysplastic syndrome (MDS) with no circulating blasts and with < 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with < 5% or 5-10% blasts in MDS). Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
Cardiac function: Left ventricular ejection fraction > 45% based on most recent echocardiogram or multigated acquisition scan (MUGA) results
Estimated creatinine clearance > 60 mL/min calculated by equation
Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin > 50% and forced expiratory volume in first second (FEV1) predicted > 50% based on most recent pulmonary function test results
Liver function acceptable per local institutional guidelines
Karnofsky performance status (KPS) of > 70%
Subjects ≥ 18 years of age or legally authorized representative must have the ability to give informed consent according to applicable regulatory and local institutional requirements.

Stratum 2 Recipient Inclusion Criteria

Age > 18 years at the time of signing informed consent
Planned NMA/RIC regimen as defined per protocol
Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age < 35 years
Product planned for infusion is PBSC

One of the following diagnoses:

Patients with acute leukemia or chronic myeloid leukemia (CML) with no circulating blasts, no evidence of extramedullary disease, and with < 5% blasts in the bone marrow. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
Patients with MDS with no circulating blasts and with < 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with < 5% or 5-10% blasts in MDS.) Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
Patients with chronic lymphocytic leukemia (CLL) or other leukemias (including prolymphocytic leukemia) with chemosensitive disease at time of transplantation
Patients with lymphoma with chemosensitive disease at the time of transplantation
Cardiac function: Left ventricular ejection fraction > 45% based on most recent echocardiogram or MUGA results with no clinical evidence of heart failure
Estimated creatinine clearance > 60 mL/min calculated by equation
Pulmonary function: DLCO corrected for hemoglobin > 50% and FEV1 predicted > 50% based on most recent pulmonary function test results
Liver function acceptable per local institutional guidelines
KPS of > 60%
Subjects ≥ 18 years of age or legally authorized representative must have the ability to give informed consent according to applicable regulatory and local institutional requirements.

Stratum 3 Recipient Inclusion Criteria

Age > 1 years and < 21 years at the time of signing informed consent
Partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age < 35 years
Product planned for infusion is BM
Planned MAC regimen as defined per protocol

One of the following diagnosis:

AML in 1st remission or beyond with ≤ 5% marrow blasts, no circulating blasts or evidence of extra-medullary disease. Pre-transplant MRD testing will be performed as per standard of practice at the treating institution. Patients with any MRD status are eligible and should be enrolled at the discretion of provider. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
Patients MDS with no circulating blasts and less than 10% blasts in the bone marrow. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
ALL in 1st remission or beyond with ≤ 5% marrow blasts, no circulating blasts, or evidence of extra-medullary disease. Pre-transplant MRD testing will be performed as standard practice at the treating institution with the goal of achieving MRD of <0.01%. Patients with any MRD status are eligible and should be enrolled at the discretion of provider. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
Other leukemia (mixed-phenotype acute leukemia [MPAL], CML, or other leukemia) in morphologic remission with ≤ 5% marrow blasts and no circulating blasts or evidence of extramedullary disease. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
Chemotherapy sensitive lymphoma in at least partial remission (PR)
KPS or Lansky performance score ≥ 70%
Cardiac function: Left ventricular ejection fraction of ≥ 50% and shortening fraction of ≥ 27% based on most recent echocardiogram
Glomerular Filtration Rate (GFR) of ≥ 60ml/min/1.73m2 measured by nuclear medicine scan or calculated from a 24 hour urine collection
Pulmonary function: DLCO corrected for hemoglobin, FEV1, and Forced Vital Capacity (FVC) of ≥50% if able to perform pulmonary function tests. If unable to perform pulmonary function tests, must have a resting pulse oximetry of >92% without supplemental oxygen.
Hepatic: Total bilirubin ≤ 2.5 mg/dL and alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 3x the upper limit of normal
Legal guardian permission must be obtained for subjects < 18 years of age. Pediatric subjects will be included in age appropriate discussion in order to obtain assent.
Subjects ≥ 18 years of age or legally authorized representative must have the ability to give informed consent according to applicable regulatory and local institutional requirements.

Donor Inclusion Criteria:

Must be unrelated to the subject and high-resolution HLA-matched at 4/8, 5/8, 6/8, or 7/8 (HLA-A, -B, -C, and -DRB1)
Donor must be typed at high-resolution for a minimum of HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1
Age > 18 years and < 35 years at the time of signing informed consent
Meet the donor registries' medical suitability requirements for PBSC or BM donation
Must undergo eligibility screening according to current Food and Drug Administration (FDA) requirements. Donors who do not meet one or more of the donor screening requirements may donate under urgent medical need.
Must agree to donate PBSC (or BM for stratum 3)
Must have the ability to give standard (non-study) informed consent according to applicable donor regulatory requirements

Recipient Exclusion Criteria (Strata 1, 2 and 3):

Suitable HLA-matched related or 8/8 high-resolution matched unrelated donor available
Subject unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing
Primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia, polycythemia vera, or MDS with grade 4 marrow fibrosis
Subjects with a prior allogeneic transplant
Subjects with an autologous transplant within the past 3 months
Females who are breast-feeding or pregnant
Uncontrolled bacterial, viral or fungal infection at the time of the transplant preparative regimen
Concurrent enrollment on other interventional GVHD clinical trial (enrollment on supportive care trials may be allowed after discussion with Principal Investigators)
Subjects who undergo desensitization to reduce anti-donor HLA antibody levels prior to transplant.
Patients who are HIV+ with persistently positive viral load. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

Donor Exclusion Criteria:

Donor unwilling or unable to donate

Recipient positive anti-donor HLA antibodies against a mismatched HLA in the selected donor determined by either:

a positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) or
the presence of anti-donor HLA antibody to any HLA locus (HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, -DPA1) with mean fluorescence intensity (MFI) >3000 by solid phase immunoassay

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 2

Estimated Enrollment:

180

Study ID:

NCT04904588

Recruitment Status:

Recruiting

Sponsor:

Center for International Blood and Marrow Transplant Research

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 32 Locations for this study

See Locations Near You

City of Hope National Medical Center
Duarte California, 91010, United States More Info
Monzr Al Malki, MD
Contact
Stanford University
Stanford California, 94305, United States More Info
Sally Arai, MD
Contact
Colorado Blood Cancer Institute
Denver Colorado, 80218, United States More Info
Alireza Eghtedar, MD
Contact
University of Florida Health Shands Hospital
Gainesville Florida, 32610, United States More Info
Nosha Farhadfar, MD
Contact
University of Miami Sylvester Cancer Center
Miami Florida, 33136, United States More Info
Antonio M Jimenez Jimenez, MD
Contact
H. Lee Moffitt Cancer Center and Research Institute
Tampa Florida, 33612, United States More Info
Farhad Khimani, MD
Contact
Children's Healthcare of Atlanta
Atlanta Georgia, 30322, United States More Info
Muna Qayed, MD
Contact
Emory University Medical Center
Atlanta Georgia, 30322, United States More Info
Amelia Langston, MD
Contact
Northwestern University
Chicago Illinois, 60611, United States More Info
Kehinde Adekola, MD
Contact
The University of Chicago
Chicago Illinois, 60637, United States More Info
Satyajit Kosuri, MD
Contact
University of Maryland Medical Center
Baltimore Maryland, 21201, United States More Info
Nancy Hardy, MD
Contact
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore Maryland, 21231, United States More Info
Javier Bolanos Meade, MD
Contact
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Mahasweta Gooptu, MD
Contact
University of Michigan Medical Center - Mott Children's Hospita
Ann Arbor Michigan, 48109, United States More Info
Mark Vander Lugt, MD
Contact
Karmanos Cancer Institute
Detroit Michigan, 48201, United States More Info
Dipenkumar Modi, MD
Contact
Mayo Clinic Rochester
Rochester Minnesota, 55905, United States More Info
William Hogan, MD
Contact
Washington University/Barnes Jewish Hospital
Saint Louis Missouri, 63110, United States More Info
Ramzi Abboud, MD
Contact
Roswell Park Comprehensive Cancer Center
Buffalo New York, 14263, United States More Info
Philip McCarthy, MD
Contact
Columbia University Medical Center
New York New York, 10032, United States More Info
Ran Reshef, MD
Contact
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Brian Shaffer, MD
Contact
University of North Carolina Chapel Hill
Chapel Hill North Carolina, 27599, United States More Info
Katarzyna Jamieson, MD
Contact
Levine Cancer Institute
Charlotte North Carolina, 28204, United States More Info
Michael Grunwald, MD
Contact
Ohio State Medical Center, James Cancer Center
Columbus Ohio, 43210, United States More Info
Karilyn Larkin, MD
Contact
Hannah Choe, MD
Contact
Oregon Health and Science University
Portland Oregon, 97239, United States More Info
Levanto Schachter, DO
Contact
University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States More Info
Alison Loren, MD
Contact
Thomas Jefferson University Sidney Kimmel Cancer Center
Philadelphia Pennsylvania, 19107, United States More Info
Usama Gergis, MD
Contact
TriStar Medical Group Children's Specialists
Nashville Tennessee, 37203, United States More Info
Haydar Frangoul
Contact
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States More Info
Bhagirathbhai Dholaria, MD
Contact
St. David's South Austin Medical Center
Austin Texas, 78704, United States More Info
Aravind Ramakrishnan
Contact
Texas Transplant Institute
San Antonio Texas, 37203, United States More Info
Julio Alvarenga, MD
Contact
University of Virginia
Charlottesville Virginia, 22903, United States More Info
Karen Ballen, MD
Contact
Virginia Commonwealth University
Richmond Virginia, 23298, United States More Info
John McCarty, MD
Contact
University of Wisconsin Hospital and Clinic
Madison Wisconsin, 53792, United States More Info
Aric Hall, MD
Contact
Froedtert & the Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States More Info
Medhi Hamadani, MD
Contact

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 2

Estimated Enrollment:

180

Study ID:

NCT04904588

Recruitment Status:

Recruiting

Sponsor:


Center for International Blood and Marrow Transplant Research

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.